TB-500 (Thymosin Beta-4)Cellular PeptideSafety Rating 6/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Swiss ChemsBest $/mgCOA ✓ · 3P | $42.36 | $4.24 | Apr 17, 2026 | Buy → $25 off $100+·auto |
| Ascension PeptidesCOA ✓ · 3P | $25.00 | $5.00 | Apr 16, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $53.96 | $5.40 | May 19, 2026 | Buy → |
| Apex Peptide SupplyCOA ✓ · 3P | $59.99 | $6.00 | May 14, 2026 | Buy → |
| Amino ClubCOA ✓ · 3P | $31.99 | $6.40 | May 14, 2026 | Buy → |
Overview
About TB-500
Mechanism of action
Upregulates actin, promotes cell migration and proliferation, inhibits inflammatory cytokines (IL-6, TNF-α), stimulates angiogenesis and neurogenesis.
Safety profile
Head rush/fatigue immediately post-injection; possible nausea; theoretical concern re: cancer proliferation (avoid with active malignancy). · Parent protein TB4 has Phase II data; fragment widely used anecdotally; proangiogenic concern theoretical
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops TB-500 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Active malignancy — TB-500 is pro-angiogenic and may theoretically accelerate tumor growth.
Pregnancy and lactation — no human safety data.
Frequently stacked with BPC-157 for tissue repair; no clinical evidence of synergy but widely reported anecdotally.
Related pages
More on TB-500
Stack & Compare
Frequently Researched Together
Learn More
TB-500 Guide
A complete guide to TB-500 (Thymosin Beta-4) — the recovery peptide.
Read full guide · 9 min read →Research
Studies & key findings
- Promotes cardiac repair by activating integrin-linked kinase (ILK) in epicardial progenitor cells, mobilizing them to regenerate damaged myocardium after MI.
- Phase 1 RCT in healthy volunteers (2010) confirmed IV thymosin β4 was safe and well-tolerated, clearing a key hurdle for clinical development.